

# Upkar S Gill

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/548927/publications.pdf>

Version: 2024-02-01

53  
papers

4,291  
citations

257450

24  
h-index

206112

48  
g-index

55  
all docs

55  
docs citations

55  
times ranked

5795  
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. <i>Journal of Hepatology</i> , 2021, 74, 567-577.	3.7	377
2	HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant. <i>Gastroenterology</i> , 2016, 151, 986-998.e4.	1.3	312
3	IL-10 <sup>hi</sup> Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection. <i>Journal of Immunology</i> , 2012, 189, 3925-3935.	0.8	310
4	Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell <sup>hi</sup> mediated deletion. <i>Journal of Experimental Medicine</i> , 2013, 210, 99-114.	8.5	286
5	IL-2 <sup>high</sup> tissue-resident T cells in the human liver: Sentinels for hepatotropic infection. <i>Journal of Experimental Medicine</i> , 2017, 214, 1567-1580.	8.5	259
6	Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis B. <i>Gastroenterology</i> , 2012, 143, 637-645.	1.3	257
7	Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. <i>Nature Medicine</i> , 2015, 21, 591-600.	30.7	226
8	CXCR6 marks a novel subset of T-bet <sup>lo</sup> Eomes <sup>hi</sup> natural killer cells residing in human liver. <i>Scientific Reports</i> , 2016, 6, 26157.	3.3	220
9	High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. <i>Journal of Hepatology</i> , 2020, 73, 705-708.	3.7	213
10	Circulating and intrahepatic antiviral B cells are defective in hepatitis B. <i>Journal of Clinical Investigation</i> , 2018, 128, 4588-4603.	8.2	208
11	Toll-Like Receptor 8 Agonist and Bacteria Trigger Potent Activation of Innate Immune Cells in Human Liver. <i>PLoS Pathogens</i> , 2014, 10, e1004210.	4.7	204
12	PD-1 blockade partially recovers dysfunctional virus <sup>hi</sup> specific B cells in chronic hepatitis B infection. <i>Journal of Clinical Investigation</i> , 2018, 128, 4573-4587.	8.2	188
13	The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells. <i>PLoS Pathogens</i> , 2013, 9, e1003208.	4.7	176
14	Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8 <sup>hi</sup> T Cells in the Same Host. <i>Cell Reports</i> , 2016, 16, 1243-1252.	6.4	176
15	Hepatitis B virus <sup>hi</sup> specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. <i>Journal of Clinical Investigation</i> , 2018, 128, 668-681.	8.2	167
16	Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection. <i>Gastroenterology</i> , 2020, 159, 652-664.	1.3	102
17	Assessment of Bone Mineral Density in Tenofovir-Treated Patients With Chronic Hepatitis B: Can the Fracture Risk Assessment Tool Identify Those at Greatest Risk?. <i>Journal of Infectious Diseases</i> , 2015, 211, 374-382.	4.0	75
18	Fine needle aspirates comprehensively sample intrahepatic immunity. <i>Gut</i> , 2019, 68, 1493-1503.	12.1	65

#	ARTICLE	IF	CITATIONS
19	Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo. <i>PLoS Pathogens</i> , 2016, 12, e1005788.	4.7	54
20	Alternative splicing of hepatitis B virus: A novel virus/host interaction altering liver immunity. <i>Journal of Hepatology</i> , 2017, 67, 687-699.	3.7	47
21	T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System. <i>Journal of Immunology</i> , 2017, 198, 1172-1182.	0.8	41
22	Liver sampling: a vital window into HBV pathogenesis on the path to functional cure. <i>Gut</i> , 2018, 67, gutjnl-2017-314873.	12.1	40
23	Differential immunogenicity of homologous versus heterologous boost in Ad26.COVS vaccine recipients. <i>Med</i> , 2022, 3, 104-118.e4.	4.4	38
24	Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B. <i>Gut</i> , 2021, 70, 2337-2348.	12.1	36
25	Innate and Adaptive Immunopathogenesis in Viral Hepatitis; Crucial Determinants of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 1255.	3.7	24
26	Chronic hepatitis B: the demise of the "inactive carrier" phase. <i>Hepatology International</i> , 2021, 15, 290-300.	4.2	22
27	The human liver microenvironment shapes the homing and function of CD4 <sup>+</sup> T-cell populations. <i>Gut</i> , 2022, 71, 1399-1411.	12.1	19
28	TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis. <i>Scientific Reports</i> , 2017, 7, 5514.	3.3	14
29	Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis. <i>Gut</i> , 2020, 69, 1907-1912.	12.1	14
30	The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics. <i>Journal of Viral Hepatitis</i> , 2019, 26, 4-15.	2.0	12
31	Current therapeutic approaches for HBV infected patients. <i>Journal of Hepatology</i> , 2017, 67, 412-414.	3.7	11
32	Reduced survival after upper gastrointestinal bleed endoscopy in the COVID-19 era is a secondary effect of the response to the global pandemic: a retrospective cohort study. <i>Frontline Gastroenterology</i> , 2021, 12, 279-287.	1.8	11
33	New insights in the management of chronic hepatitis B. <i>Clinical Medicine</i> , 2015, 15, 191-196.	1.9	10
34	Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UK. <i>Frontiers in Medicine</i> , 2021, 8, 642723.	2.6	10
35	Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 978-993.	3.7	9
36	Clinical Trial Design for Immune-Based Therapy of Hepatitis B Virus. <i>Seminars in Liver Disease</i> , 2017, 37, 085-094.	3.6	8

#	ARTICLE	IF	CITATIONS
37	CD4 T cells in hepatitis B virus: "You don't have to be cytotoxic to work here and help". Journal of Hepatology, 2020, 72, 9-11.	3.7	7
38	Chronic hepatitis B virus in young adults: the need for new approaches to management. Expert Review of Anti-Infective Therapy, 2014, 12, 1045-1053.	4.4	6
39	Assessing immunological and virological responses in the liver: Implications for the cure of chronic hepatitis B virus infection. JHEP Reports, 2022, 4, 100480.	4.9	6
40	Early Treatment Consideration in Patients with Hepatitis B "e" Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift?. Viruses, 2022, 14, 900.	3.3	6
41	HCMV jogs the "memory" of NK cells in HBV. Journal of Hepatology, 2019, 70, 343-345.	3.7	5
42	Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels <i>in vivo</i> , hinder HBsAg secretion <i>in vitro</i> and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. Emerging Microbes and Infections, 2020, 9, 928-939.	6.5	5
43	The $\beta$ -NGF/TrkA Signalling Pathway Is Associated With the Production of Anti-Nucleoprotein IgG in Convalescent COVID-19. Frontiers in Immunology, 2021, 12, 813300.	4.8	5
44	Emerging tools in the changing landscape of chronic hepatitis B management. Expert Review of Anti-Infective Therapy, 2019, 17, 943-955.	4.4	4
45	Early treatment of chronic hepatitis B in children: Everything to play for?. Journal of Hepatology, 2020, 72, 802-803.	3.7	1
46	We need to talk about #livertwitter. Journal of Hepatology, 2021, 75, 1239-1240.	3.7	1
47	HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation. Biomedicine, 2021, 9, 1352.	3.2	1
48	Making safe sense of an anti-sense!. Cell Reports Medicine, 2022, 3, 100503.	6.5	1
49	Effect of prednisolone therapy on monocyte phenotype and function in alcoholic hepatitis. Lancet, The, 2016, 387, S103.	13.7	0
50	Effect of in-vivo hepatitis B viral load suppression after interferon exposure on natural killer and T-cell responsiveness. Lancet, The, 2017, 389, S39.	13.7	0
51	Quantification of intrahepatic total HBV DNA in liver biopsies of HBV-infected patients by a modified version of COBAS <sup>®</sup> Ampliprep/COBAS <sup>®</sup> TaqMan HBV test v2.0. Medical Microbiology and Immunology, 2017, 206, 295-299.	4.8	0
52	SAT-190-Specific genetic elements in HBsAg C-terminus profoundly affect HBsAg levels in vivo, hamper HBsAg secretion in vitro and alter HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection. Journal of Hepatology, 2019, 70, e713-e714.	3.7	0
53	IDDF2020-ABS-0163...Reduced survival post-endoscopy for upper gastrointestinal bleeding in the COVID-19 era is a secondary effect of the response to the global pandemic. , 2020, , .		0